- Home
- ZYME vs SSTK Comparison
ZYME vs SSTK Comparison
Compare ZYME & SSTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZYME
- SSTK
- Stock Information
- Founded
- ZYME 2003
- SSTK 2003
- Country
- ZYME United States
- SSTK United States
- Employees
- ZYME N/A
- SSTK N/A
- Industry
- ZYME Biotechnology: Pharmaceutical Preparations
- SSTK EDP Services
- Sector
- ZYME Health Care
- SSTK Technology
- Exchange
- ZYME Nasdaq
- SSTK Nasdaq
- Market Cap
- ZYME 983.6M
- SSTK 1.1B
- IPO Year
- ZYME 2017
- SSTK 2012
- Fundamental
- Price
- ZYME $14.39
- SSTK $25.38
- Analyst Decision
- ZYME Buy
- SSTK Buy
- Analyst Count
- ZYME 6
- SSTK 4
- Target Price
- ZYME $19.17
- SSTK $50.33
- AVG Volume (30 Days)
- ZYME 340.7K
- SSTK 414.3K
- Earning Date
- ZYME 03-05-2025
- SSTK 02-25-2025
- Dividend Yield
- ZYME N/A
- SSTK 5.20%
- EPS Growth
- ZYME N/A
- SSTK N/A
- EPS
- ZYME N/A
- SSTK 1.01
- Revenue
- ZYME $62,199,000.00
- SSTK $902,175,000.00
- Revenue This Year
- ZYME $21.53
- SSTK $9.51
- Revenue Next Year
- ZYME N/A
- SSTK $12.56
- P/E Ratio
- ZYME N/A
- SSTK $25.16
- Revenue Growth
- ZYME N/A
- SSTK 3.09
- 52 Week Low
- ZYME $7.97
- SSTK $25.13
- 52 Week High
- ZYME $17.70
- SSTK $54.41
- Technical
- Relative Strength Index (RSI)
- ZYME 49.88
- SSTK 29.71
- Support Level
- ZYME $14.45
- SSTK $28.45
- Resistance Level
- ZYME $15.25
- SSTK $29.96
- Average True Range (ATR)
- ZYME 0.73
- SSTK 1.17
- MACD
- ZYME -0.02
- SSTK -0.45
- Stochastic Oscillator
- ZYME 64.58
- SSTK 3.57
About ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated product candidates. Its clinical candidate, zanidatamab, is a novel Azymetric HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About SSTK Shutterstock Inc.
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market.